Candel Therapeutics shares rise 10.10% intraday after Stephens & Co. reaffirms Overweight rating with $15 target and company hosts virtual R&D day outlining virology and oncology pipeline.

jueves, 11 de diciembre de 2025, 10:41 am ET1 min de lectura
CADL--
Candel Therapeutics surged 10.10% in intraday trading, following Stephens & Co. reaffirming an "Overweight" rating with a $15 price target and the company hosting a virtual R&D day outlining its virology and oncology pipeline.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios